| Today's Big NewsFeb 8, 2023 |
|
April 3 - 4, 2023 | San Diego, CA Connect with leading communications professionals and have honest, open discussions about how to develop your career in the industry. Early Bird Rate Ends February 10th.
|
|
| By Max Bayer With few avenues available to budding biotechs looking for funding, the pressure to ink licensing agreements was palpable at the Biotechnology Innovation Organization's CEO and Investor Conference in New York. |
|
|
|
By Annalee Armstrong Johnson & Johnson has yet to publicly detail the R&D overhaul reported last week by Fierce Pharma, and, apparently, at least one company with work that may be deprioritized or reorganized is waiting in the lurch. |
By Gabrielle Masson While COVID-19 may have briefly held down the average cost of developing a drug while inflating the potential returns, the party is well and truly over. At least that's what a report from Deloitte indicates, with Big Pharma back on the pre-pandemic path of spending ever more to make a medicine with shrinking rewards to show for it. |
By Fraiser Kansteiner Almost a year to the day after Pfizer launched its suit against Regor and two former employees at the head of the biotech—Min Zhong and Xiayang Qiu—U.S. Magistrate Judge Thomas Farrish has ordered the Big Pharma to fork over 35 emails and text messages with the FBI related to the defendants. |
|
Read this expert chat log for insights into successfully achieving
investigatory goals and regulatory submission... Read More >>
|
|
By Nick Paul Taylor SK bioscience has taken a look at the receding COVID-19 vaccine market and its own stuttering effort to win share and decided to double down, outlining plans to invest $261 million in a R&D hub designed to establish it as a leading force in the global response to new infectious diseases. |
By Nick Paul Taylor Failed clinical trials have put Vistagen on edge. After seeing two rival social anxiety disorder candidates flunk phase 2 studies, the biotech has paused plans to resume a phase 3 trial of its own once-failed prospect PH94B pending talks with the FDA. |
By Gabrielle Masson Five years after the formation of the FDA’s Oncology Center of Excellence, the federal center slowed the launch of new projects to focus on existing programs, with particular focus on ramping up four programs to help modernize clinical cancer trials. |
By Helen Floersh Clinicians and researchers have suspected for years that the aggressive, less-common form of MS is likely a distinct disease. Now, new research conducted using a more accurate mouse model confirms it. |
By Joseph Keenan CRO hVIVO inked a £6.8 million ($8.2 million) deal with an unnamed pharmaceutical company to run a human challenge test for a respiratory syncytial virus antiviral drug candidate. |
By Angus Liu The calls for a new Bayer CEO have been answered. Bill Anderson, most recently Roche’s pharma chief, will become Bayer’s new group CEO starting in April. |
By Paige Minemyer Rumors swirled last month at the J.P. Morgan Healthcare Conference that CVS Health had finally found its primary care play: acquiring Oak Street Health. The healthcare giant confirmed those rumors Wednesday morning. |
By Conor Hale The artificial intelligence program is designed to provide real-time feedback to clinicians conducting cardiac ultrasound exams. |
By Teresa Carey In this week's episode of "Podnosis," we discuss how providers can and should recognize and respond to the culturally diverse needs of the Latino community. We also talk about what private healthcare plans can do given the explosion of enrollment in ACA exchanges. |
Fierce podcastsDon't miss an episode |
| This week on "The Top Line," we discuss what we can expect from the obesity market in 2023. We also recap the drugs approved last year. |
|
|---|
|
|
|
March 14-15, 2023 | San Francisco, CA Uncover flexible partnership models, licensing deals, M&A opportunities, and innovative deal structures to maximize potential and ensure a successful and profitable collaboration. Register today to secure our lowest rates!
|
|
| Whitepaper Discover the Power of Small with NanoplasmidTM – the next-generation plasmid for manufacturing today’s cell and gene therapies. Sponsored by: Aldevron |
| WhitepaperThis paper explores the cost drivers behind gene therapies and how they are likely to evolve in the coming years. Sponsored by: Blue Matter |
| WhitepaperExploring the biology of G Protein-Coupled Receptors (GPCRs) and outlining a novel approach for developing therapeutics against previously undruggable GPCRs Sponsored by: Orion Biotechnology |
| WhitepaperLearn more about critical success factors for your next launch based on the experience of 100+ pharma product launches. Sponsored by: Herspiegel Consulting |
| WhitepaperRCTs with digital twins require fewer control patients and shorten trial timelines for Alzheimer's disease. Sponsored by: Unlearn AI |
| Whitepaper What makes nucleotides suitable for current good manufacturing practices? Sponsored by: Thermo Fisher Scientific |
| On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| |
|
